RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Bernard Arulanandam to Cystatins

Back to Details
This is a "connection" page, showing publications Bernard Arulanandam has written about Cystatins.
Bernard Arulanandam
Connection Strength
0.442
Cystatins
  1. Holloway AJ, Yu J, Arulanandam BP, Milligan GN, Eaves-Pyles TD. Combination of Cystatins 9 and C Modulates Serum Biomarkers Associated with Inflammation and Provides Prophylactic as Well as Long-Term Protection against Multidrug-Resistant Klebsiella pneumoniae. Antimicrob Agents Chemother. 2019 05; 63(5).
    View in: PubMed
    Score: 0.170
  2. Holloway AJ, Yu J, Arulanandam BP, Hoskinson SM, Eaves-Pyles T. Cystatins 9 and C as a Novel Immunotherapy Treatment That Protects against Multidrug-Resistant New Delhi Metallo-Beta-Lactamase-1-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2018 03; 62(3).
    View in: PubMed
    Score: 0.157
  3. Eaves-Pyles T, Patel J, Arigi E, Cong Y, Cao A, Garg N, Dhiman M, Pyles RB, Arulanandam B, Miller AL, Popov VL, Soong L, Carlsen ED, Coletta C, Szabo C, Almeida IC. Immunomodulatory and antibacterial effects of cystatin 9 against Francisella tularensis. Mol Med. 2013 Aug 28; 19:263-75.
    View in: PubMed
    Score: 0.115
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support